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Identity 
Other names: AITRL, GITRL, MGC138237, TL6 




2 transcript versions published: 
mRNA 748 bp: 3 exons (1-223, 224-254, 255-748) -> 
coding for 199 aa (2-601), 
mRNA 610 bp: 3 exons (1-176, 177-207, 208-610) -> 
coding for 177 aa (21-554). 
Transcription 
Accurate start codon is not clearly defined, 2 transcript 






TNFSF18/GITR ligand (GITRL) is a single-pass type 
II transmembrane protein and contains 2 potential 
glycosylation sites (predicted at 129 aa and 161 aa). 
TNFSF18 encompasses 177 or 199 aa and thus has a 
molecular weight of about 20 kDa. In the 177 aa long 
version, amino acids 1-28 constitute the cytoplasmic 
domain, 29-49 the transmembrane domain, and 50-177 
the extracellular domain, whereas in the 199 aa long 
variant the amino acids 1-50 constitute the cytoplasmic 
domain, 51-71 the transmembrane domain, and 72-199 
the extracellular domain. 
Expression 
TNFSF18 is expressed on DC, monocytes, 
macrophages, B cells, activated T cells, endothelial 
cells, osteoclasts and various healthy non-lymphoid 
tissues (e.g., testis, ...).  
 
Figure 1. Schematic illustration of the gene structure of human TNFSF18 on chromosome 1. Both published transcript variants are 
shown. Red boxes represent the mRNA transcript within the gene. The smaller boxes at the beginning and the end of the transcripts 
indicate untranslated regions, while the larger boxes display the translated parts. 
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Figure 2. Schematic illustration of the structure of TNFSF18 protein versions, according to the two published transcripts. 
 
The fact that TNFSF18 is constitutively expressed on 
resting antigen-presenting cells distinguishes it from 
most other TNF family members, which are not 
detectable in resting state and are upregulated 
following activation. 
In addition, TNFSF18 is constitutively expressed and 
released as soluble form by solid tumors of different 
histological origin and various hematopoietic 
malignancies. 
Localisation 
TNFSF18 is a type II transmembrane protein. A soluble 
form of the molecule has been shown to be released by 
a yet unknown mechanism e.g. by tumor cells. 
Function 
TNFSF18 is the only known ligand for GITR 
(TNFRSF18, AITR), which is mainly expressed by 
lymphatic cells like T lymphocytes and NK cells. Upon 
interaction with its receptor, TNFSF18 is, like many 
other TNF family members, capable to transduce 
bidirectional signals, i.e. in the receptor and the ligand 
bearing cell. Transduction of signals into TNFSF18 
bearing cells has been shown to cause differentiation of 
osteoclasts, to activate macrophages and to alter 
cytokine production of healthy myeloid cells, but also 
of carcinoma and leukemia cells and influences 
apoptosis. Activation of macrophages via TNFSF18 
results in increased secretion of inflammatory 
mediators like MMP-9, NO and TNF. In healthy 
macrophages and myeloid leukemia cells, TNFSF18 
signaling has been found to involve the MAP kinase 
pathway. 
Binding to TNFRSF18 may induce signaling through 
this receptor, which, in mice, has been implicated in the 
development of autoimmune diseases, graft versus host 
disease and in the immune response against infectious 
pathogens and tumors. 
Available data suggest that TNFRSF18 may mediate 
different effects in mice and men, and most functional 
studies regarding the role of TNFRSF18 in tumor 
immunology have been performed using agonistic 
antibodies or injection of adenovirus expressing 
recombinant TNFSF18 into tumors, which might not 
reflect the consequences of TNFRSF18 interaction with 
its natural ligand in vivo. In line, studies evaluating 
immune responses in GITR
-/-
 mice have so far not led 
to a clear picture of the role of TNFRSF18 in normal 
physiology. 
Homology 
The TNFSF18 gene is conserved in human, 
chimpanzee, dog, mouse, and rat. The homology 








In mice, it has been shown that application of the 
agonistic GITR antibody DTA-1 delays tumor 
progression and can even lead to complete tumor 
rejection. Similar results were obtained by using 
GITRL-Fc fusion protein. Transfection of tumor cells 
with GITRL causes rejection of the tumor and 
prolonged survival, while parental cells cannot be 
rejected. This effect can be reversed by administration 
of a blocking GITRL antibody. There is evidence that 
expression of GITRL promotes the development of 
tumor-specific T cells. Re-challenge of mice which 
once successfully rejected GITRL-positive tumor 
results in complete rejection of both transfected and 
non-transfected tumors. Several studies showed 
increased infiltration of CD8+ cells in GITRL-
expressing tumors. By the use of depletion experiments 
and athymic nude mice it has been shown that for 
GITR-GITRL dependent rejection of tumors both 
CD4+ and CD8+ T cells as well as NK cells are 
required. 
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In humans, controversial data regarding the function of 
GITR and GITRL in tumor immunology were 
described. Hanabuchi et al. reported that NK cells are 
activated by engagement of GITRL on plasmacytoid 
dendritic cells, which can be blocked by anti-GITRL 
antibody. In contrast, Baltz et al. and Baessler et al. 
demonstrated substantial GITRL expression on tumor 
cells and leukemic blasts resulting in diminished NK 
cell reactivity. Blockade of GITR-GITRL interaction 
by anti-GITR antibody abrogated the inhibitory effect 
of GITRL. Furthermore, stimulation of GITRL 
substantially induced the production of TGF-beta and 
IL-10 by tumor cells and leukemic blasts. Additionally, 
they reported that human GITRL is released by tumor 
cells in a soluble form which impairs NK cell reactivity 
alike the membrane-bound form. Thus, GITRL 
expression seems to affect the interaction of human 
tumor cells with the immune system by influencing 
tumor cell immunogenity and metastasis and creating 
an immunosuppressive cytokine microenvironment. 
The inhibitory effect of GITRL on human NK cells was 
further supported by Liu et al., who reported inhibition 
of NK cell proliferation and cytokine production and 
increased apoptosis after GITR stimulation. These 
controversial data regarding the function of GITR on 
human NK cells may be due to the usage of different 
reagents and different experimental condition. 
The results regarding the role of GITR and GITRL in 
tumor immunology are controversial in mice and 
humans. Thus, GITR and GITRL may mediate 
different effects in mice and men, and in line 
suppression of human regulatory T cells, in contrast to 
their murine counterparts, is not inhibited by GITR. 
Many studies employed agonistic antibodies or 
recombinant protein for GITR stimulation and not 
constitutively GITRL-expressing cells. Thus, these 
studies do not involve possible influences of reverse 
signaling mediated by GITRL, which may change 
reaction of GITRL-bearing cells and may in turn alter 
functions of GITR-bearing cells. 
Autoimmune disease 
Note 
The influence of GITR and GITRL was tested in 
different mouse models of autoimmune disease. Onset 
of autoimmune diabetes in NOD mice is accelerated if 
they are treated with agonistic GITR mAb, and 
activation of CD4+ T cells is increased compared to 
control treated mice. Likewise, application of a 
blocking GITRL antibody protected from diabetes. In 
GITR -/- mice, experimental autoimmune diseases take 
an attenuated course. GITR -/- mice with collagen-
induced arthritis show less joint inflammation and bone 
erosion than wildtype mice. Furthermore, lower 
concentrations of inflammatory mediators were 
reported. In line with these findings, GITR triggering 
antibody exacerbates collagen-induced arthritis in 
wildtype mice compared to control-treated siblings. 
However, all these studies regarding the function of 
GITR and its ligand in autoimmune disease were 
performed in mice. Further investigation is needed to 
elucidate the relevance of GITR and GITR ligand in 
human autoimmune disease and to clarify the 
similarities and differences of these molecules in mice 
and men. 
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